Because monoclonal gammopathy and multiple myeloma develop at different ages in Vκ*-MYC (as in humans), mice were paired according to age, baseline total, and monoclonal IgG concentrations, and one of each pair was either treated with recombinant C3d or injected with PBS, that is left untreated. This evidence concerns the gene MYC and monoclonal gammopathy.